pharmaceutical investing Ironwood and Alnylam Enter US GI Disease Education and Promotional Agreement
pharmaceutical investing Approval of Linzess Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation
pharmaceutical investing Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C
Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease
Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth
Apex Commences Drilling at Jersey Emerald Property and Announces Amendment to Terms of Lithium Creek Option Agreement
